Longeveron (LGVN) Cash from Financing Activities (2020 - 2026)
Longeveron (LGVN) posted quarterly Cash from Financing Activities of $15.5 million for Q1 2026, up 26801.72% year-over-year from N/an in Q1 2025, and up 1893.18% quarter-over-quarter from $777000.0 in Q4 2025.
Longeveron (LGVN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Longeveron's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $15.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 26801.72% year-over-year to $15.5 million; the TTM figure through Mar 2026 stood at $20.2 million (down 29.49% YoY), while the FY2025 annual figure was $4.7 million, down 83.78% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $15.5 million, up from $777000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $15.5 million in Q1 2026, with the low at -$193000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is -$27000.0 (2022), against an average of $3.2 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 678.95% in 2022, then surged 27548.0% in 2024.
- Longeveron's Cash from Financing Activities stood at -$193000.0 in 2022, then surged by 2905.7% to $5.4 million in 2023, then tumbled by 100.92% to -$50000.0 in 2024, then jumped by 1654.0% to $777000.0 in 2025, then surged by 1893.18% to $15.5 million in 2026.
- Business Quant data shows LGVN's Cash from Financing Activities at $15.5 million in Q1 2026, $777000.0 in Q4 2025, and $4.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 75,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75,000.00 |
| Jun 30, 2026 | 75,000.00 |
| Mar 31, 2026 | 15.49 Mn |
| Mar 31, 2026 | 15.49 Mn |
| Dec 31, 2025 | 777,000.00 |
| Dec 31, 2025 | 777,000.00 |
| Sep 30, 2025 | 4.08 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | -133,000.00 |
| Jun 30, 2025 | -133,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Sep 30, 2024 | 13.72 Mn |
| Sep 30, 2024 | 13.72 Mn |
| Jun 30, 2024 | 15.05 Mn |
| Jun 30, 2024 | 15.05 Mn |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |